Novozymes Biopharma, part of Novozymes, world leader in bioinnovation, will be showcasing its pioneering Bacillus-based Hyaluronic Acid (bHA) at the 2010 International Conference on Hyaluronan, 6-11 June in Kyoto, Japan. The company will also launch its first pilot cGMP compliant sample program for this novel source of HA and will be delivering a series of informative, educational presentations.
Novozymes Biopharma’s booth will feature the world’s first and only recombinant source of HA, produced without the use of animal-derived raw materials or organic solvents. This innovative approach to producing HA product is based on Novozymes Biopharma’s patented, safe fermentation and purification technology which results in a highly consistent and pure product. The production system is based on Bacillus subtilis, a well-characterized, non-pathogenic and endotoxin-free organism that is considered safe by the US Food and Drug Administration (FDA).
In addition to providing a ‘hands-on’ demonstration area of Hyaluronic Acid, Novozymes Biopharma will also be providing bHA pilot samples ahead of the launch of the company’s new state-of-the-art Q7 cGMP compliant HA facility in Tianjin, China. This new facility is due to come on line in Q1, 2011 and will be dedicated to the production of HA for medical applications.
Dr. Khadija Schwach-Abdellaoui, Senior R&D Manager at Novozymes Biopharma, has been invited to deliver a 30 minute presentation on “HyaCare – New Preferred Biopolymer Template for Medical Devices and Drug Delivery Systems”. In addition, two new technical posters will be presented by Novozymes Biopharma at the conference, demonstrating the many advantages of bHA over conventional rooster comb and Streptococcus derived HAs.
To learn more about Bacillus-based Hyaluronic Acid and the company’s pilot sample program, please visit Novozymes Biopharma at the 2010 International Conference on Hyaluronan. Alternatively please email Sally Vernon, Customer Communications Manager, at SYKE[.]novozymes.com.
Novozymes (novozymes.com) is the world leader in bioinnovation. Together with customers across a broad array of industries we create tomorrow’s industrial biosolutions, improving our customers' business and the use of our planet's resources.
With over 700 products used in 130 countries, Novozymes’ bioinnovations improve industrial performance and safeguard the world’s resources by offering superior and sustainable solutions for tomorrow’s ever-changing marketplace.
Novozymes’ natural solutions enhance and promote everything from removing trans fats in cooking, to advancing biofuels to power the world tomorrow. Our never-ending exploration of nature’s potential is evidenced by over 6,000 patents, showing what is possible when nature and technology join forces.
Our 5,000+ employees working in research, production and sales around the world are committed to shaping business today and our world tomorrow.
Sally Vernon, Customer Communications Manager
Press and media
T: +45 4446 0690
M: +45 3077 0690
T: +45 4446 2274
M: +45 3077 2274
Paige Donnelly (USA)
T: +1 919 494 3209
M: +1 919 218 4501
T: +45 4446 8682
M: +45 3077 8682
Thomas Bomhoff (USA)
T: +1 919 494 3483
M: +1 919 649 2565.